Overview

Platelet Aggregation in Diabetic Patients With Acute Coronary Syndrome Treated With Different Doses of Aspirin

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
0
Participant gender:
All
Summary
Diabetes is an important risk factor of coronary atherosclerosis, and it's well known that platelets of diabetic patients are hyper reactive and so resistant to common antithrombotic therapy. Moreover, in diabetic patients platelets are characterized by high turnover that is responsible of lack of protection by cardioaspirin at common dosage. The aim of our study is to asses the efficacy of different doses of aspirin in diabetic patients with acute coronary syndrome.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Federico II University
Treatments:
Aspirin
Criteria
Inclusion Criteria:

- Diabetic patients with acute coronary syndrome after 24 hours from the coronarography

Exclusion Criteria:

- patients with a family or personal history of bleeding or thrombophilic disorders;

- platelet count >600000/mmc or <150000/mmc

- hematocrit >50% or <25%

- creatinine clearance <30 mL/min